VILNIUS — Fermentas, one of Lithuania’s biggest biotechnology companies, is on the verge of being sold to American technology giant Thermo Fisher Scientific for 728 million litai (€211,000).

The impending sale is a validation of government rhetoric that Lithuania has high scientific skills and is a good place for research facilities. Fermentas is one of the few companies in the country that can retain scientists before they move abroad.

The final amount that will be paid for [private_supervisor]the company is unclear as the deal needs be cleared by supervisory bodies. It is expected that the deal will go down this autumn.

The exact amount of the transaction after it is clear supervisory authority and the signing of definitive agreements for the sale. The transaction is expected to complete this year’s third quarter.

The Americans are interested in an enzyme that the company produced.

“The enzyme produces a wide range of molecular biology reagents needed for research, also for conducting research, and its acquisition would strengthen the Thermo Fisher Scientific Unit,” the company said.

“With enzymes we can better serve your needs as specialists in molecular biology and they will be able to accelerate research and improve performance,” Thermo Fisher Scientific’s president Marc Caspers said in a press release.

Fermentas director Viktoras Butkus lauded the deal.

“Thermo Fisher is a global life sciences industry leader and is being connected to such well-known companies will make us able to create new attractive opportunities for its customers and employees,” Butkus said.

Thermo Fisher Scientific – the company’s shares are listed on the New York Stock Exchange. Its market value – about 21 billion. USD. Last year, the company’s revenues amounted to 10.5 billion. USD (about 29 billion. Com), which is about as far as this year’s planned expenditure of Lithuanian national budget. [/private_supervisor] [private_subscription 1 month]the company is unclear as the deal needs be cleared by supervisory bodies. It is expected that the deal will go down this autumn.

The exact amount of the transaction after it is clear supervisory authority and the signing of definitive agreements for the sale. The transaction is expected to complete this year’s third quarter.

The Americans are interested in an enzyme that the company produced.

“The enzyme produces a wide range of molecular biology reagents needed for research, also for conducting research, and its acquisition would strengthen the Thermo Fisher Scientific Unit,” the company said.

“With enzymes we can better serve your needs as specialists in molecular biology and they will be able to accelerate research and improve performance,” Thermo Fisher Scientific’s president Marc Caspers said in a press release.

Fermentas director Viktoras Butkus lauded the deal.

“Thermo Fisher is a global life sciences industry leader and is being connected to such well-known companies will make us able to create new attractive opportunities for its customers and employees,” Butkus said.

Thermo Fisher Scientific – the company’s shares are listed on the New York Stock Exchange. Its market value – about 21 billion. USD. Last year, the company’s revenues amounted to 10.5 billion. USD (about 29 billion. Com), which is about as far as this year’s planned expenditure of Lithuanian national budget. [/private_subscription 1 month] [private_subscription 4 months]the company is unclear as the deal needs be cleared by supervisory bodies. It is expected that the deal will go down this autumn.

The exact amount of the transaction after it is clear supervisory authority and the signing of definitive agreements for the sale. The transaction is expected to complete this year’s third quarter.

The Americans are interested in an enzyme that the company produced.

“The enzyme produces a wide range of molecular biology reagents needed for research, also for conducting research, and its acquisition would strengthen the Thermo Fisher Scientific Unit,” the company said.

“With enzymes we can better serve your needs as specialists in molecular biology and they will be able to accelerate research and improve performance,” Thermo Fisher Scientific’s president Marc Caspers said in a press release.

Fermentas director Viktoras Butkus lauded the deal.

“Thermo Fisher is a global life sciences industry leader and is being connected to such well-known companies will make us able to create new attractive opportunities for its customers and employees,” Butkus said.

Thermo Fisher Scientific – the company’s shares are listed on the New York Stock Exchange. Its market value – about 21 billion. USD. Last year, the company’s revenues amounted to 10.5 billion. USD (about 29 billion. Com), which is about as far as this year’s planned expenditure of Lithuanian national budget.
[/private_subscription 4 months] [private_subscription 1 year]the company is unclear as the deal needs be cleared by supervisory bodies. It is expected that the deal will go down this autumn.

The exact amount of the transaction after it is clear supervisory authority and the signing of definitive agreements for the sale. The transaction is expected to complete this year’s third quarter.

The Americans are interested in an enzyme that the company produced.

“The enzyme produces a wide range of molecular biology reagents needed for research, also for conducting research, and its acquisition would strengthen the Thermo Fisher Scientific Unit,” the company said.

“With enzymes we can better serve your needs as specialists in molecular biology and they will be able to accelerate research and improve performance,” Thermo Fisher Scientific’s president Marc Caspers said in a press release.

Fermentas director Viktoras Butkus lauded the deal.

“Thermo Fisher is a global life sciences industry leader and is being connected to such well-known companies will make us able to create new attractive opportunities for its customers and employees,” Butkus said.

Thermo Fisher Scientific – the company’s shares are listed on the New York Stock Exchange. Its market value – about 21 billion. USD. Last year, the company’s revenues amounted to 10.5 billion. USD (about 29 billion. Com), which is about as far as this year’s planned expenditure of Lithuanian national budget. [/private_subscription 1 year]

— This is a paid article. To subscribe or extend your subscription, click here.